A Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Explore the Immunogenicity of the Tuberculosis (TB) Vaccine Candidate QTP101 (ID93+GLA-SE) in Older Adults (Aged 55~74 Years)
Overview
- Phase
- Phase 1
- Intervention
- QTP101
- Conditions
- Tuberculosis, Pulmonary
- Sponsor
- Quratis Inc.
- Enrollment
- 144
- Locations
- 4
- Primary Endpoint
- Safety Endpoint - Immediate Adverse Events
- Status
- Recruiting
- Last Updated
- 10 months ago
Overview
Brief Summary
The purpose of this study is to evaluate the safety and explore the immunogenicity of ID93+GLA-SE compared to placebo following three intramuscular (IM) injections on Days 0, 28 and 56 in the Bacillus Calmette-Guérin (BCG)-vaccinated older adults aged 55 to 74 with negative or positive result on the QuantiFERON-TB (QFT) test. Eligible participants will be randomly assigned based on age group and the QFT test results to receive either QTP101 (Dose 1 and Dose 2) or placebo.
Safety and immunogenicity will be monitored from the first dose until 12 months after the final dose of the investigational product. Blood samples for immunogenicity analysis will be collected at five-time points: before the first dose (Day 0), 4 weeks after the first dose (Day 28), 4 weeks after the second dose (Day 56), 4 weeks after the third dose (Day 84), and 48 weeks after the third dose (Day 392). Once the safety and immunogenicity follow-up is completed 48 weeks after the third dose (Day 392) for the last enrolled participant, a final report will be compiled based on the collected data.
Detailed Description
This Phase 1 randomized, double-blind, placebo-controlled clinical trial aims to evaluate the safety and explore the immunogenicity of the investigational tuberculosis (TB) vaccine candidate QTP101 (ID93+GLA-SE) in healthy and medically stable older adults aged 55-74 years. The study targets two specific age groups-55-64 years (middle-aged) and 65-74 years (elderly)-to address the unmet need for effective TB prevention in populations with high disease prevalence and risk, particularly in countries with an aging population. The trial involves three treatment arms: Low-dose vaccine group: 2 μg ID93 + 5 μg GLA-SE High-dose vaccine group: 10 μg ID93 + 5 μg GLA-SE Placebo group: Normal saline (0.9%) Participants will receive three intramuscular (IM) injections of their assigned treatment at baseline (Day 0), Day 28, and Day 56. They will be monitored for safety and immunogenicity over 12 months, with regular follow-up visits scheduled at 1, 6, and 12 months post-final injection. Key Study Elements: Eligibility Criteria: Participants must be BCG-vaccinated, HIV-negative, and have QuantiFERON-TB Gold (QFT) test results positive or negative. Chronic conditions are permissible if well-controlled. Women of childbearing potential and men must use approved contraception methods during the study. Safety Monitoring: Adverse events (AEs) will be closely monitored, categorized as immediate AEs (within 30 minutes of vaccination), solicited local/systemic AEs (within 7 days), unsolicited AEs (up to 28 days), and serious AEs (SAEs) monitored until 12 months post-final dose. Immunogenicity Assessments: Blood samples will be collected pre-vaccination and at multiple intervals (Day 28, 56, 84, and 392) to measure ID93-specific antibody titers (ELISA) and Th1 cytokine responses (ICS). Sentinel Design for Older Adults: To ensure participant safety, a sentinel group design is employed for cohorts aged 65-74. Initial vaccination will proceed sequentially within smaller sentinel subgroups, with further cohort enrollment contingent on DSMB approval after reviewing safety data. Study Objective: This trial aims to establish the safety profile and preliminary immunogenicity of QTP101 as a step toward addressing the persistent global burden of TB, particularly in vulnerable older populations. The results will inform subsequent clinical development phases to optimize the vaccine's dosing and application. The study's results will provide critical insights into TB vaccine strategies for aging populations, ensuring a foundation for broader preventative interventions.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Participants who can comply with all scheduled assessment visits during the clinical trial period and who can be continuously monitored by the investigator through the provided contact information
- •Males or females aged 55 to 74 years at the time of consent
- •Participants and/or legally authorized representatives who are capable of providing written informed consent (signed in person in the presence of a witness)
- •Participants with either positive or negative QFT test results at the time of screening; QFT testing can be omitted in the following case: If participants have a documented history of a positive QFT test result, evidenced by submitted records or recorded in the EMR
- •Participants with negative HIV test results at the time of screening
- •Participants with a record of BCG vaccination or BCG scar directly
- •Participants who fall within the following range in physical measurements at the time of screening: 19 ≤ Body Mass Index (BMI) ≤ 33 (kg/m\^2) BMI and weight results are rounded to the nearest whole number.
- •Healthy participants or those with well-managed chronic diseases through medical history and clinical examination
- •Female participants must provide evidence at the screening visit (Visit 1) that they meet one of the following criteria to be considered non-fertile:
- •Non-fertile: Defined as post-menopausal or other infertility conditions. Post-menopausal women: No menstrual periods for at least 12 months after stopping all external hormone treatments and over 55 years old. Documented irreversible surgical infertility such as hysterectomy, bilateral oophorectomy, or bilateral salpingectomy. However, tubal ligation is not permitted.
Exclusion Criteria
- •Participants who meet any of the following criteria must be excluded from enrollment.
- •Participants who are suspected of having tuberculosis, have a history of tuberculosis, are currently undergoing treatment for tuberculosis, are being treated for latent tuberculosis infection, or have a history of medication treatment for latent tuberculosis infection at the time of the Screening (Visit 1) or the first administration (Visit 2)
- •Participants who have received other investigational products or used unapproved drugs within 6 months prior to participating in the clinical trial or who plan to use them during the trial period
- •Participants who have previously received an investigational tuberculosis vaccine
- •Participants who test positive for HIV at the screening visit
- •Participants who test positive for HCV or who test positive for HBsAg and negative for HBsAb in HBV tests at the screening visit
- •Participants who are exposed to or will be exposed to investigational or non-investigational products during the clinical trial period or who participate in another clinical trial simultaneously
- •Participants who have received immunoglobulins and/or any blood products within 90 days before the first administration of the investigational product or plan to receive them during the clinical trial period
- •Pregnant or breastfeeding female
- •Participants with the following medical or psychiatric conditions that make it impossible to conduct the clinical trial as judged by the principal investigator:
Arms & Interventions
BCG-vaccinated, HIV-negative, QFT-negative and middle-aged adults (55-64) with a low dose of QTP101
This study arm evaluates the safety and immunogenicity of a low dose of QTP101 in BCG-vaccinated, HIV-negative, QFT-negative adults aged 55-64. Participants receive 2 μg of ID93 and 5 μg of GLA-SE via intramuscular injection on Day 0, Day 28, and Day 56. The target population includes individuals without prior TB infection as indicated by the QFT-negative status. The primary objective is to assess safety, focusing on adverse events (AEs), and to explore immunogenicity through antibody titers and cytokine responses. Findings will provide critical insights into the vaccine's effects in middle-aged, previously uninfected individuals.
Intervention: QTP101
BCG-vaccinated, HIV-negative, QFT-negative and middle-aged adults (55-64) with a high dose of QTP101
This study arm evaluates the safety and immunogenicity of a high dose of QTP101 in BCG-vaccinated, HIV-negative, QFT-negative adults aged 55-64. Participants receive 10 μg of ID93 and 5 μg of GLA-SE via intramuscular injection on Day 0, Day 28, and Day 56. This group focuses on individuals without prior TB infection, as indicated by their QFT-negative status. The primary objective is to assess the safety profile, including adverse events (AEs), and to evaluate the immune response, such as antibody titers and cytokine production. The findings will help determine the vaccine's suitability for middle-aged individuals and guide future dose optimization.
Intervention: QTP101
BCG-vaccinated, HIV-negative, QFT-negative and middle-aged adults (55-64) with the placebo
This study arm serves as a placebo comparator for BCG-vaccinated, HIV-negative, QFT-negative adults aged 55-64. Participants receive intramuscular injections of sterile normal saline (placebo) on Day 0, Day 28, and Day 56. The purpose of this arm is to provide a baseline for evaluating the safety and immunogenicity outcomes of QTP101 by comparing the incidence of adverse events (AEs) and immune responses against those observed in the experimental groups. This group includes individuals without prior TB infection, as indicated by their QFT-negative status, and is essential for assessing the specific effects of the investigational vaccine.
Intervention: Placebo
BCG-vaccinated, HIV-negative, QFT-negative and older adults (65-74) with a low dose of QTP101
This study arm evaluates the safety and immunogenicity of a low dose of QTP101 in BCG-vaccinated, HIV-negative, QFT-negative older adults aged 65-74. Participants receive 2 μg of ID93 and 5 μg of GLA-SE via intramuscular injection on Day 0, Day 28, and Day 56. This arm focuses on individuals without prior TB infection, as indicated by their QFT-negative status. The primary objective is to assess the safety profile, including adverse events (AEs), and to explore the vaccine's immunogenicity through antibody titers and cytokine responses. The findings will provide key data on the vaccine's effects in older, previously uninfected populations.
Intervention: QTP101
BCG-vaccinated, HIV-negative, QFT-negative and older adults (65-74) with a high dose of QTP101
This study arm investigates the safety and immunogenicity of a high dose of QTP101 in BCG-vaccinated, HIV-negative, QFT-negative older adults aged 65-74. Participants receive 10 μg of ID93 and 5 μg of GLA-SE via intramuscular injection on Day 0, Day 28, and Day 56. The arm focuses on individuals without prior TB infection, as indicated by their QFT-negative status. The primary aim is to evaluate the safety profile, including adverse events (AEs), and to assess the immunogenicity of the high-dose vaccine through antibody titers and cytokine production. The findings will help determine the vaccine's suitability and dose optimization for older populations.
Intervention: QTP101
BCG-vaccinated, HIV-negative, QFT-negative and older adults (65-74) with the placebo
This study arm serves as a placebo comparator for BCG-vaccinated, HIV-negative, QFT-negative older adults aged 65-74. Participants receive intramuscular injections of sterile normal saline (placebo) on Day 0, Day 28, and Day 56. The purpose of this arm is to establish a baseline for safety and immunogenicity assessments by comparing the incidence of adverse events (AEs) and immune responses against those observed in the experimental groups. This group includes individuals without prior TB infection, as indicated by their QFT-negative status, and plays a crucial role in evaluating the specific effects of the investigational vaccine.
Intervention: Placebo
BCG-vaccinated, HIV-negative, QFT-positive and middle-aged adults (55-64) with a low dose of QTP101
This study arm evaluates the safety and immunogenicity of a low dose of QTP101 in BCG-vaccinated, HIV-negative, QFT-positive middle-aged adults aged 55-64. Participants receive 2 μg of ID93 and 5 μg of GLA-SE via intramuscular injection on Day 0, Day 28, and Day 56. This arm targets individuals with prior latent or resolved TB infection, as indicated by their QFT-positive status. The primary objective is to assess the safety profile, focusing on adverse events (AEs), and to explore the vaccine's immunogenicity through antibody titers and cytokine responses. The results will provide valuable data on the vaccine's performance in previously exposed middle-aged adults.
Intervention: QTP101
BCG-vaccinated, HIV-negative, QFT-positive and middle-aged adults (55-64) with a high dose of QTP101
This study arm investigates the safety and immunogenicity of a high dose of QTP101 in BCG-vaccinated, HIV-negative, QFT-positive middle-aged adults aged 55-64. Participants receive 10 μg of ID93 and 5 μg of GLA-SE via intramuscular injection on Day 0, Day 28, and Day 56. This arm focuses on individuals with prior latent or resolved TB infection, as indicated by their QFT-positive status. The primary goal is to assess the safety profile, including adverse events (AEs), and to evaluate the immunogenicity of the high-dose vaccine by measuring antibody titers and cytokine responses. The findings will inform dose optimization and vaccine effectiveness in previously exposed middle-aged adults.
Intervention: QTP101
BCG-vaccinated, HIV-negative, QFT-positive and middle-aged adults (55-64) with the placebo
This study arm serves as a placebo comparator for BCG-vaccinated, HIV-negative, QFT-positive middle-aged adults aged 55-64. Participants receive intramuscular injections of sterile normal saline (placebo) on Day 0, Day 28, and Day 56. The purpose of this arm is to establish a baseline for evaluating the safety and immunogenicity outcomes of QTP101 in individuals with prior latent or resolved TB infection, as indicated by their QFT-positive status. This comparison will help identify the specific effects of the investigational vaccine by contrasting it with the placebo group in terms of adverse events (AEs) and immune responses.
Intervention: Placebo
BCG-vaccinated, HIV-negative, QFT-positive and older adults (65-74) with a low dose of QTP101
This study arm evaluates the safety and immunogenicity of a low dose of QTP101 in BCG-vaccinated, HIV-negative, QFT-positive older adults aged 65-74. Participants receive 2 μg of ID93 and 5 μg of GLA-SE via intramuscular injection on Day 0, Day 28, and Day 56. This arm targets individuals with prior latent or resolved TB infection, as indicated by their QFT-positive status. The primary objective is to assess the safety profile, focusing on adverse events (AEs), and to explore the vaccine's immunogenicity through antibody titers and cytokine responses. The findings will provide critical insights into the vaccine's safety and effectiveness in previously exposed older populations.
Intervention: QTP101
BCG-vaccinated, HIV-negative, QFT-positive and older adults (65-74) with a high dose of QTP101
This study arm investigates the safety and immunogenicity of a high dose of QTP101 in BCG-vaccinated, HIV-negative, QFT-positive older adults aged 65-74. Participants receive 10 μg of ID93 and 5 μg of GLA-SE via intramuscular injection on Day 0, Day 28, and Day 56. This arm focuses on individuals with prior latent or resolved TB infection, as indicated by their QFT-positive status. The primary goal is to assess the safety profile, including adverse events (AEs), and to evaluate the vaccine's immunogenicity through antibody titers and cytokine responses. The results will inform dose optimization and effectiveness of the vaccine in older adults with prior TB exposure.
Intervention: QTP101
BCG-vaccinated, HIV-negative, QFT-positive and older adults (65-74) with the placebo
This study arm serves as a placebo comparator for BCG-vaccinated, HIV-negative, QFT-positive older adults aged 65-74. Participants receive intramuscular injections of sterile normal saline (placebo) on Day 0, Day 28, and Day 56. The purpose of this arm is to establish a baseline for evaluating the safety and immunogenicity of QTP101 in individuals with prior latent or resolved TB infection, as indicated by their QFT-positive status. Comparing this group to the experimental arms will help identify the specific effects of the investigational vaccine in terms of adverse events (AEs) and immune responses.
Intervention: Placebo
Outcomes
Primary Outcomes
Safety Endpoint - Immediate Adverse Events
Time Frame: Within 30 minutes after each administration
Immediate adverse events within 30 minutes after administration
Safety Endpoint - Solicited local and systemic Adverse Events
Time Frame: Occurred up to 7 days after each administration
Solicited local/systemic AEs occurred up to 7 days after administration
Safety Endpoint - Unsolicited local and systemic Adverse Events
Time Frame: Occurred up to 28 days after each administration
Unsolicited local/systemic AEs occurred up to 28 days after administration
Safety Endpoint - Serious Adverse Events and Adverse Event of of Special Interest
Time Frame: Occurred from the first administration up to 48 weeks after the last administration
Serious AE (SAEs) and AE of special interest (AESI) occurred from the first administration up to 48 weeks after the last administration
Safety Endpoint - Laboratory assessment (Hematological Test)
Time Frame: From screening to the end of visit at 48 weeks after the last administration
Hematological test for each participant
Safety Endpoint - Laboratory assessment (Hematochemical test)
Time Frame: From screening to the end of visit at 48 weeks after the last administration
Hematochemical test for each participant
Safety Endpoint - Laboratory assessment (Urine test)
Time Frame: From screening to the end of visit at 48 weeks after the last administration
Urine test for each participant
Safety Endpoint - Vital Signs (Body temperature)
Time Frame: From screening to the end of visit at 48 weeks after the last administration
Body weight will be measured at each scheduled visit after the administration of the investigational product for each participant.
Safety Endpoint - Vital Signs (Pulse)
Time Frame: From screening to the end of visit at 48 weeks after the last administration
Pulse rate will be measured for each participant.
Safety Endpoint - Vital Signs (Respiratory rate)
Time Frame: From screening to the end of visit at 48 weeks after the last administration
Respiratory rate will be measured for each participant.
Safety Endpoint - Vital Signs (Blood pressure)
Time Frame: From screening to the end of visit at 48 weeks after the last administration
Systolic and diastolic blood pressure will be measured for each participant.
Immunogenicity Endpoint - Humoral immunity (GMT)
Time Frame: Before 1st administration, 4 weeks after 1st administration, 4 weeks after 2nd administration, 4 and 48 weeks after 3rd administration
Geometric mean titer (GMT) of antigen-specific IgG measured with ELISA
Immunogenicity Endpoint - Humoral immunity (GMFR)
Time Frame: Before 1st administration, 4 weeks after 1st administration, 4 weeks after 2nd administration, 4 and 48 weeks after 3rd administration
Geometric mean fold rise (GMFR) of antigen-specific IgG measured with ELISA
Immunogenicity Endpoint - Humoral immunity (SRR)
Time Frame: Before 1st administration, 4 weeks after 1st administration, 4 weeks after 2nd administration, 4 and 48 weeks after 3rd administration
Seroresponse rate (SRR), defined as a 4-fold rise in antibody titer of antigen-specific IgG measured with ELISA from Baseline
Immunogenicity Endpoint - Cellular immunity (ICS)
Time Frame: Before 1st administration, 4 weeks after 1st administration, 4 weeks after 2nd administration, 4 and 48 weeks after 3rd administration
The ratio and amount of antigen-specific Th1 cytokine-secreting cells measured with intracellular cytokine staining (ICS)
Immunogenicity Endpoint - Cellular immunity (RR)
Time Frame: Before 1st administration, 4 weeks after 1st administration, 4 weeks after 2nd administration, 4 and 48 weeks after 3rd administration
Cell response rate (RR), defined as a 4-fold rise in the amount of antigen-specific Th1 cytokine-secreting cells from the baseline.
Safety Endpoint - Physical examinations (General Appearance)
Time Frame: At screening, the second and third administrations, 4, 24 and 48 weeks after the last administration.
Overall health and appearance, including posture and obvious abnormalities.
Safety Endpoint - Physical examinations (Skin)
Time Frame: At screening, the second and third administrations, 4, 24 and 48 weeks after the last administration.
Inspection for rashes, lesions, discoloration, or other visible skin issues
Safety Endpoint - Physical examinations (Head/Neck)
Time Frame: At screening, the second and third administrations, 4, 24 and 48 weeks after the last administration.
Examination of the skull, scalp, lymph nodes, and thyroid gland
Safety Endpoint - Physical examinations (Chest/Lungs)
Time Frame: At screening, the second and third administrations, 4, 24 and 48 weeks after the last administration.
Assessment of respiratory sounds, chest wall movement, and breathing patterns using inspection and auscultation
Safety Endpoint - Physical examinations (Heart)
Time Frame: At screening, the second and third administrations, 4, 24 and 48 weeks after the last administration.
Evaluation of heart sounds, rhythm, and potential murmurs through auscultation and palpation
Safety Endpoint - Physical examinations (Abdomen)
Time Frame: At screening, the second and third administrations, 4, 24 and 48 weeks after the last administration.
Palpation and auscultation for organ enlargement, tenderness, or abnormal bowel sounds
Safety Endpoint - Physical examinations (Genitourinary System)
Time Frame: At screening, the second and third administrations, 4, 24 and 48 weeks after the last administration.
Examination of genital and urinary organs, focusing on abnormalities or patient-reported symptoms (if applicable)
Safety Endpoint - Physical examinations (Limbs)
Time Frame: At screening, the second and third administrations, 4, 24 and 48 weeks after the last administration.
Inspection and assessment for swelling, deformities, or movement limitations
Safety Endpoint - Physical examinations (Musculoskeletal System)
Time Frame: At screening, the second and third administrations, 4, 24 and 48 weeks after the last administration.
Examination of joints, muscles, and bones for pain, swelling, or restricted mobility
Safety Endpoint - Physical examinations (Nervous System)
Time Frame: At screening, the second and third administrations, 4, 24 and 48 weeks after the last administration.
Assessment of reflexes, motor and sensory functions, and coordination
Safety Endpoint - Physical examinations (Other)
Time Frame: At screening, the second and third administrations, 4, 24 and 48 weeks after the last administration.
Any additional assessments based on the participant's symptoms or clinical findings